Pooling clinical experiences of patients treated with Lutetium-177 in Spain

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study collects and analyzes data from Spanish medical centers treating patients with somatostatin receptor positive tumors using Lutetium-177. The aim is to evaluate the efficacy, safety, and tolerance of this treatment in routine clinical practice. Patient data will be gathered retrospectively from medical records after obtaining informed consent, focusing on the profiles of patients and tumors treated. The study will provide insights into treatment outcomes across various types of neuroendocrine tumors.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Written informed consent must be obtained prior to any data collection.
* Patients must be diagnosed with unresectable or metastatic, progressive, somatostatin receptor positive tumour
* Aged ≥18 years.

Exclusion Criteria:

* None

Where it's running

• Hospital Clínico Universitario de Santiago
  Santiago de Compostela, A Coruña, Spain Recruiting
• Hospital Universitario Virgen de las Nieves
  Granada, Andalusia, Spain Recruiting
• Hospital Unviersitari Son Espases
  Palma de Mallorca, Balearic Islands, Spain Recruiting
• Hospital Clínico Universitario Virgen de la Arrixaca
  El Palmar, Murcia, Spain Recruiting
• Clínica Universidad de Navarra
  Pamplona, Navarre, Spain Recruiting
• Hospital Universitario Central de Asturias
  Oviedo, Principality of Asturias, Spain Recruiting

Study contacts

• Principal investigator: Mercedes Dr Mitjavila Casanovas, MD-PhD — Sociedad Española de Medicina Nuclear e Imagen Molecular (SEMNIM)
• Study coordinator: Mercedes Dr Mitjavila Casanovas, MD-PhD
• Email: mercedes.mitjavila@salud.madrid.org
• Phone: 911916000

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• PF-08634404 plus chemotherapy for adults with metastatic colorectal cancer

  This trial will test whether adding a new drug called PF-08634404 to standard chemotherapy helps adults whose colorectal cancer has spread.

  Recruiting at 343 sites Phase 3 Pfizer · Chandler, Arizona and 371 other locations · NCT07222800

• Using a virus therapy to treat recurrent cerebellar brain tumors in children

  This study is testing a new virus treatment for children with recurring brain tumors to see if it can help them get better when combined with a low dose of radiation.

  Recruiting at 3 sites Phase 1 M.D. Anderson Cancer Center · Birmingham, Alabama and 2 other locations · NCT03911388

• Combination of Anlotinib and TQB2450 for Esophageal Cancer Treatment

  This study is testing if combining two medications, Anlotinib and TQB2450, can help people with esophageal cancer stay cancer-free after surgery.

  Recruiting Phase 2 Jiangxi Provincial Cancer Hospital · Nanchang, Jiangxi · NCT05252078

• High-sensitivity blood test to detect and monitor multiple cancers

  This study will test a high-sensitivity blood test that looks for tumor DNA to detect and follow several common cancers in adults with those cancers or people having routine health screenings.

  Recruiting Yonsei University · Seoul · NCT07035587

• Anti-mesothelin TNhYP218 CAR T cell therapy for mesothelin-expressing solid tumors

  This treatment will test whether a person's own engineered CAR T cells that target mesothelin can help adults with mesothelin-expressing solid tumors, including mesothelioma, that have returned or spread after standard therapy.

  Recruiting Phase 1 National Institutes of Health Clinical Center (CC) · Bethesda, Maryland · NCT06885697

• Evaluating HTL0039732 for Advanced Solid Tumours

  This study is testing a new drug called HTL0039732, alone and with another treatment, to see if it can help people with advanced solid tumors by boosting their immune response against cancer.

  Recruiting at 6 sites Phase 1/2 Cancer Research UK · Cambridge and 5 other locations · NCT05944237

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.